Pfizer Consumer Healthcare, a division of Pfizer, Inc., is voluntarily recalling six lots of its ThermaCare® HeatWrap product.

The company stated in a press release that they started this recall because product from these lots has a potential to leak ingredients that are found inside the heat cell wrap.

The press release said that the use of a leaking or damaged heat cell wrap could cause skin injuries such as burns/blisters and/or skin irritation on the area where the wrap is applied.

The product label warns not to use the product if heat cell contents leak or the wrap is damaged or torn.

The ThermaCare® HeatWrap lots impacted are:

S68516 (Muscle Pain Therapy 3+1 count carton), 

T26686 (Muscle Pain Therapy 3 count carton)

T26691 (Menstrual Pain Therapy 3 count carton)

T26693 (Menstrual Pain Therapy 3+1 count carton)

8054HA and 8054HB (11 count bundled packages contain one (1) package of Muscle Therapy Heatwraps, 

8HR (3 Count) and two (2) packages of Joint Therapy Heatwraps

8HR (4 Count)

The lots in question were sent nationwide to retailers, wholesalers, and distributors in the United States, Puerto Rico and the U.S. Virgin Islands from September 2017 through August 2018.

Pfizer Consumer Healthcare said they are removing the product from store shelves and asking consumers who have purchased and are still in possession of the affected product to discontinue use of the products, record the lot number, throw the product away in its entirety without opening the foil pouch, and to please contact the Pfizer Consumer Healthcare Information Line at 1-800-323-3383 (Mon-Fri, 9 am-5 pm EST) for replacement or reimbursement. 

Note: The lot numbers can be found on the side of ThermaCare cartons and on the back of ThermaCare pouches.

If people have questions regarding this recall or to report an adverse event or product complaint, contact the Pfizer Consumer Healthcare Information Line at 1-800-323-3383 (Mon-Fri, 9 am-5 pm EST).

People should contact their healthcare provider if they have experienced any problems that may be related to using this product.

Adverse reactions or quality problems experienced with the use of this product may also be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.